Introduction. Antiphospholipid syndrome (APS) is an autoimmune disorder causing thrombosis with a potential risk for recurrence. Thrombotic APS therapy is based on long-term coagulation, still, new therapies are under study: targeting inflammation, immune modulation and complement inhibition. However, before establishing the right therapy, it is important to understand the mechanisms of APS.
Objective of the study. The aim of the study was to evaluate the significance of high-sensitivity C reactive protein (hs-CRP), P selectin and sCD40L serum levels as predictors of recurrent thrombotic events in patients with antiphospholipid syndrome.
Material and method. Forty-one patients with APS, diagnosed according to the revised Sapporo classification for APS criteria were included in the study.
Results. High titers of hs-CRP were correlated to high titers of aCL (r = 0.38; p = 0.014) and to high P selectin levels (r = 0.296; p = 0.05). There was a significant correlation between the serum levels of P selectin and the number of recurrent thrombotic events (r = 0.368; p = 0.018).
Conclusion. Platelet activation and inflammation occur in patients with APS and P selectin and hs-CRP proved to predict the evolution with recurrent thrombosis in patients with APS.
Key words: hs-CRP, antiphospholipid syndrome, aCL, P selectin.
List of abbreviations:
APS: Antiphospholipid syndrome
hs-CRP: high-sensitivity C reactive protein
aPL: antiphospholipid antibodies
SLE: systemic lupus erythematous
IL-1: Interleukin 1
sCD40L: Soluble CD40-ligand
PAPS: primary antiphospholipid syndrome
aCL: anticardiolipin antibodies